首页> 美国卫生研究院文献>ACS Medicinal Chemistry Letters >Design and Synthesis of 4-(4-Benzoylaminophenoxy)phenolDerivatives As Androgen Receptor Antagonists
【2h】

Design and Synthesis of 4-(4-Benzoylaminophenoxy)phenolDerivatives As Androgen Receptor Antagonists

机译:4-(4-苯甲酰基氨基苯氧基)苯酚的设计与合成作为雄激素受体拮抗剂的衍生物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We report the design and synthesis of novel 4-(4-benzoylaminophenoxy)phenol derivatives that bind to the androgen receptor (AR) ligand-binding domain and exhibit potent androgen-antagonistic activity. Compound >22 is one of the most potent of these derivatives, inhibiting the dihydrotestosterone-promoted growth of SC-3 cell line bearing wild-type AR (IC50 0.75 μM), LNCaP cell line bearing T877A-mutated AR (IC50 0.043 μM), and 22Rv1 cell line bearing H874Y-mutated AR (IC50 0.22 μM). Structure–activity relationship studies confirmed that the pharmacophore of these novel AR antagonists is distinct from the nitro- or cyano-substituted anilide substructure of other nonsteroidal AR antagonists. This novel pharmacophore is expected to provide a basis for designing new antiprostate cancer agents.
机译:我们报告设计和合成的新型4-(4-苯甲酰氨基苯氧基)苯酚衍生物与雄激素受体(AR)配体结合域结合,并表现出强大的雄激素拮抗活性。化合物> 22 是这些衍生物中最有效的衍生物之一,可抑制双氢睾酮促进的带有野生型AR(IC50 0.75μM)的SC-3细胞系,带有T877A突变的AR的LNCaP细胞系的生长(IC50 0.043μM)和带有H874Y突变AR的22Rv1细胞系(IC50 0.22μM)。结构与活性之间的关系研究证实,这些新型AR拮抗剂的药效团不同于其他非甾体AR拮抗剂的硝基或氰基取代的苯胺亚结构。该新型药效基团有望为设计新型抗前列腺癌药物提供基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号